Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Full description

Saved in:
Bibliographic Details
Main Authors: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Format: Article
Language:English
Published: Philipps-Universität Marburg 2023
Subjects:
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

PDF Full Text

Holdings details from
Call Number: urn:nbn:de:hebis:04-es2024-04183
Publication Date: 2024-01-16
Source: Erstveröffentlichung: Völkel S, Tarawneh TS, Sacher L, Bhagwat AM, Karim I, Mack HID, Wiesmann T, Beutel B, Hoyer J, Keller C, Renz H, Burchert A, Neubauer A, Graumann J, Skevaki C and Mack EKM (2023) Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib. Front. Med. 10:1176427. https://doi.org/10.3389/fmed.2023.1176427
Downloads: 33 (2024)
License: https://creativecommons.org/licenses/by/4.0
Access URL: https://archiv.ub.uni-marburg.de/es/2024/0418
https://doi.org/10.3389/fmed.2023.1176427